Monitoring the safety of COVID-19 vaccination in pregnancy in the UK : A national study using the UK Obstetric Surveillance System (UKOSS), UK Teratology Information Service (UKTIS) and Vaccination in Pregnancy (VIP) safety monitoring systems
© The Author(s) 2022..
Background: COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection.
Methods: Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15th June 2021.
Results: There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS (n = 493) and VIP (n = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common (n = 501, 55.2%), most women were vaccinated in their second or third trimester (n = 566, 62.3%), and were mainly vaccinated due to occupational infection risk (n = 577, 63.5%).
Conclusion: Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Obstetric medicine - 16(2023), 1 vom: 17. März, Seite 40-47 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Richardson, Jonathan L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 vaccine |
|---|
| Anmerkungen: |
Date Revised 02.05.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/1753495X221076713 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356281493 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356281493 | ||
| 003 | DE-627 | ||
| 005 | 20231226070130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1753495X221076713 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356281493 | ||
| 035 | |a (NLM)37124763 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Richardson, Jonathan L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monitoring the safety of COVID-19 vaccination in pregnancy in the UK |b A national study using the UK Obstetric Surveillance System (UKOSS), UK Teratology Information Service (UKTIS) and Vaccination in Pregnancy (VIP) safety monitoring systems |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2022. | ||
| 520 | |a Background: COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection | ||
| 520 | |a Methods: Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15th June 2021 | ||
| 520 | |a Results: There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS (n = 493) and VIP (n = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common (n = 501, 55.2%), most women were vaccinated in their second or third trimester (n = 566, 62.3%), and were mainly vaccinated due to occupational infection risk (n = 577, 63.5%) | ||
| 520 | |a Conclusion: Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a SARS-coV-2 | |
| 650 | 4 | |a obstetric surveillance | |
| 650 | 4 | |a pharmacovigilance | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a teratology | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Stephens, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Chappell, Lucy C |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Amirthalingam, Gayatri |e verfasserin |4 aut | |
| 700 | 1 | |a O'Boyle, Shennae |e verfasserin |4 aut | |
| 700 | 1 | |a Bukasa, Antoaneta |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Marian |e verfasserin |4 aut | |
| 700 | 1 | |a Hodson, Kenneth K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obstetric medicine |d 2008 |g 16(2023), 1 vom: 17. März, Seite 40-47 |w (DE-627)NLM253587972 |x 1753-495X |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:1 |g day:17 |g month:03 |g pages:40-47 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1753495X221076713 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 1 |b 17 |c 03 |h 40-47 | ||